Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Living Cell Technologies Limited (LCT.AX)

ASX - ASX Delayed Price. Currency in AUD
0.01600.0000 (0.00%)
As of 10:15AM AEDT. Market open.
Advertisement

Living Cell Technologies Limited

Tower 2
Level 16 Darling Park 201 Sussex Street
Sydney, NSW 2000
Australia
61 3 8689 9997
https://www.lctglobal.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Bernard Tuch B.Sc., BSc, FRACP, GAICD, MBBS, MBBS (Hons), Ph.D.Interim Chief Exec. Officer142.92kN/A1951
Mr. Daya UkaChief Financial Officer174.98kN/AN/A
Dr. Belinda Di BartoloChief Operations Officer145.45kN/AN/A
Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSPCompany Sec.N/AN/A1964
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.

Corporate Governance

Living Cell Technologies Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement